14 results about "Small artery" patented technology

The invention belongs to the technical field of medicines, and discloses an application of a small molecule compound in preparation of a product for preventing and / or treating pulmonary arterial hypertension and complications thereof. The small molecule compound is 8-[[4-(cyclopropanecarbonyl) piperazine-1-yl] methyl]-1, 3-dimethyl-7-(3-methylbutyl) purine-2, 6-diketone, and the structural formula is as shown in a formula (I): # imgabs0. The small molecule compound and pharmaceutically acceptable salts thereof have a remarkable treatment effect on pulmonary arterial hypertension and complications thereof, and can be used for treating pulmonary arterial hypertension and complications thereof. The effects of preventing and / or treating the pulmonary arterial hypertension include the reduction of right heart hypertrophy, the reduction of right ventricular systolic pressure, right heart enlargement, right heart dysfunction, pulmonary vascular remodeling, pulmonary arterial intima thickness, increase of vascular myelization, pulmonary arterial smooth muscle cell proliferation and migration, the reduction of the right ventricular hypertrophy, the reduction of the right ventricular hypertrophy, the reduction of the right ventricular hypertrophy and the reduction of the right ventricular hypertrophy. The pulmonary arterial intima thickness and the vascular myelization level are improved, pulmonary vascular remodeling is reversed, and pulmonary artery smooth muscle cell proliferation and migration are inhibited.

A personalized whole-brain small artery angiogenesis method based on multiple constraints, belonging to the field of mathematical modeling algorithm development, includes the following steps: constructing a personalized three-dimensional model based on real head and carotid CTA images to determine the starting position of blood vessel growth; recording the geometric parameters (such as outlet area, outlet blood vessel length, etc.) of each blood vessel model based on the personalized model; using the Brainstorm standard head model three-dimensional point cloud file, uniformly sampling it as the ending position of blood vessel growth; based on multiple constraints, using the simulated annealing algorithm to optimize the geometric parameters of small blood vessels and calculate the spatial positions of bifurcations of blood vessels at all levels after meeting the constraints. The personalized whole-brain small artery angiogenesis real model of the present invention improves the accuracy for numerical simulation and hemodynamic calculation.

The invention belongs to the field of in-vitro diagnostic reagents, and particularly relates to application of a reagent for detecting biomarkers in serum in preparation of a cerebral arterial thrombosis diagnostic kit. The invention determines that the concentrations of lactic acid, isoleucine, fumaric acid, ketoglutaric acid, hypoxanthine, tyrosine, histidine and inosine in serum of a cerebral arterial thrombosis (IS) patient are significantly related to major atherosclerosis (LAA) and minor artery occlusion (SAO), so that the concentrations of the biomarkers can be used as a basis for diagnosing IS and distinguishing LAA and SAO.

A pro-inflammatory and vasoconstrictor and endothelin-1 (ET-1) are pathogenic molecules related to a series of cardiovascular diseases. Unlike ET-1 signaling for vasoconstriction of the main artery, we have proven herein that coronary microvessels exhibit a unique signaling mechanism for constriction (independent of PKC, CPI-17, and intracellular calcium storage). The pathophysiological level of ET-1 acts preferentially on the microvessels to exert persistent vasoconstriction by activating Rho kinase upon binding to ETAR of the ET-1 receptor. The ETAR antagonist BQ123 only blocks but cannot reverse vasoconstriction against ET-1. In contrast, ROCK inhibitors (e.g., H-1152) are effective to reverse arteriolar systole against ET-1. Thus, ROCK inhibition is a potent and specific choice for the treatment of coronary ischemic disease (abnormal vasoconstriction) associated with microvascular dysfunction due to excessive production of ET-1. The ROCK inhibitors may also be used to treat microvascular diseases associated with diabetic retinopathy as well as microvascular dysfunction caused by cancer therapy or immunosuppressive drugs. Since H-1152 can also reduce the basal tension of microvessels, a ROCK inhibitor is also a good diagnostic agent when used during angiography or by a non-invasive method.

The invention discloses a cerebrovascular reactivity evaluation method for non-invasive calculation of a breath-holding index, and belongs to the field of hemodynamics numerical calculation and multi-scale modeling. The method comprises the following steps: constructing a one-dimensional (1D) arteriole hemodynamic model based on an allotactic scale law; constructing a main artery three-dimensional (3D) model, and coupling the main artery three-dimensional (3D) model with the arteriole one-dimensional model and the microcirculation zero-dimensional (0D) model to form a whole-brain 3D-1D-0D geometric multi-scale hemodynamic model; based on blood flow related data obtained in the experiment process, parameterization description is conducted on arteriole radius changes and microcirculation resistance changes; a breath holding index (BHI) is calculated by numerical solution of the geometric multi-scale model. According to the method, the non-invasive numerical calculation of the breath-holding index can be realized without directly implementing a breath-holding experiment or an external stimulation condition, and a stable and repeatable calculation means is provided for quantitative analysis and related engineering application of cerebrovascular hemodynamic behaviors.

The invention discloses an application of trimethylamine oxide (TMAO) in predicting collateral circulation establishment, if collateral circulation is established, the concentration of TMAO in plasma is reduced, and if the concentration of TMAO is increased, collateral artery formation after myocardial infarction or lower limb artery occlusion can be remarkably inhibited. The invention discloses for the first time that TMAO directly hinders formation of ischemic tissue collateral circulation by inhibiting reperfusion and remodeling of middle and small arteries; the TMAO level is reduced through diet limitation or drug inhibition, and collateral artery generation and blood flow recovery of a mouse heart and lower limb ischemia model can be remarkably promoted. The invention discloses the TMAO as a novel biomarker of collateral circulation disorder and a pathological mechanism of the TMAO, and provides a theoretical basis and a technical support for non-surgical treatment and precise intervention of ischemic diseases.

The present invention describes a system and method for accessing small arteries for delivering a catheter to a target vessel, such as a cerebral vessel. In particular, the present invention describes a system that allows for direct introduction of a catheter through a vascular opening without an external sheath. The distal tip of the catheter is protected by a protective cover. Methods for introducing the catheter into the vessel and a kit are also described.

The present invention relates to the field of medical data monitoring technology, and in particular to a dynamic pulse monitoring and analysis system for cardiovascular diseases. The system utilizes a pulse big data analysis module to analyze the pulse information of all disease samples in a current large database. Based on the statistics of the pulse information, the pathological correlation degree of each pulse with the cardiovascular disease can be determined. By separately analyzing the pulse ratio information in two time periods and combining it with the pathological correlation degree, the cardiovascular monitoring attention of each patient can be quantified. Combining the elasticity decrease of the large arteries and the emergency performance of the small arteries can more effectively reflect the overall monitoring attention of each patient. Based on the overall monitoring attention, medical staff can focus on monitoring key patients. The present invention improves the efficiency of pulse monitoring and avoids delays in the condition of key patients.

The application discloses a blood pressure calculation method and equipment based on cross-scale fluid-solid coupling and considering nonlinear biomechanical characteristics of an aorta, and the method comprises the following steps: establishing a three-dimensional ideal aorta geometric model; establishing a zero-dimensional heart lumped parameter model to simulate the process that the heart pumps blood to the aorta inlet through periodic contraction and diastole; establishing a zero-dimensional three-element Windkessel model of small arteries to simulate blood flow microcirculation of peripheral small arteries; establishing a blood vessel wall biomechanical model containing residual stress of the aorta wall and active contraction of smooth muscle cells to obtain a pressure-radius relationship of the aorta wall as a fluid wall boundary condition to simulate the change process of the aorta radius in blood circulation; and coupling the three-dimensional ideal geometric model of the aorta, the zero-dimensional heart lumped parameter model and the zero-dimensional three-element Windkessel model to construct a cross-scale fluid-solid coupling system of hemodynamics, and the blood pressure in the aorta is calculated through iterative solution.

The invention relates to the technical field of medical data monitoring, in particular to a dynamic pulse condition monitoring and analyzing system for cardiovascular diseases. According to the system, the pulse condition big data analysis module is used for analyzing pulse condition information of all disease samples in the current big database, and the pathological association degree of each pulse condition to the cardiovascular disease can be determined based on statistics of the pulse condition information. The pulse condition proportion information in two time periods is independently analyzed, and the cardiovascular monitoring attention degree of each patient can be quantified in combination with the pathological association degree. The overall monitoring attention degree of each patient is more effectively reflected by combining the main artery elasticity decline degree and the small artery emergency expression degree, and medical staff can carry out key monitoring on key patients based on the overall monitoring attention degree. The pulse condition monitoring efficiency is improved, and disease delay of key patients is avoided.

The invention discloses an air bag adjusting type artery flow limiter, which belongs to the technical field of medical instruments and comprises a flow limiter and a flow limiting implanter. The flow limiter comprises an arterial stent and a flow limiting component; flow limiting control over a blood flow channel can be achieved through the double-layer air bag structure composed of the outer-layer flow limiting part and the inner-layer flow limiting part, the flow limiting implanter is filled with gas to expand the arterial stent of the net-shaped cylinder structure, the whole arterial stent expands outwards, and therefore the supporting size of the arterial stent is increased; after filling liquid is injected into the flow limiting component to enable the whole flow limiting component to be filled and expanded, a channel for blood circulation in the middle of the arterial stent can be narrowed, the blood flow is reduced by narrowing the blood flow channel, and the purposes of reducing the pressure in an arterial blood vessel and reducing the risk conditions of vascular rupture, bleeding and the like are achieved.

There was a need for safe and effective treatments for pulmonary hypertension, especially pulmonary arterial hypertension (PAH). The inventors discovered dysregulation of the kynurenine pathway (KP) in the lungs of PAH patients, marked by an imbalance of KP metabolites and upregulation of key enzymes, particularly kynurenine 3-monooxygenase (KMO). This disclosure pertains to a kynurenine-3-monooxygenase inhibitor for use in the treatment or prevention of pulmonary hypertension, in particular pulmonary arterial hypertension. The kynurenine-3- monooxygenase inhibitor is effective in reducing vascular and cardiac remodeling, decreasing right ventricular systolic pressure, reducing pulmonary ventricular resistance, decreasing medial hypertrophy of large arteries, lowering the proportion of muscularized and occluded small arteries and decreasing right ventricular hypertrophy.

A method for evaluating the efficacy of cerartinib treatment for PAH in subjects suffering from PAH, and a method for increasing the ratio of distal pulmonary artery volume to proximal pulmonary artery volume (BV510ARatio) by administering an effective dose of cerartinib to the subject are also provided. A method for increasing the pulmonary vascular volume of small arteries and reducing hypertrophy of larger pulmonary artery vessels by administering an effective dose of cerartinib to subjects who require it is also provided.

The invention provides application of circular nucleic acid circMFN2 as well as a composition and a delivery method thereof in treatment of pulmonary arterial hypertension, and belongs to the technical field of nucleic acid drugs, the circMFN2 is formed by circling splicing of exons 3 and 4 of an MFN2 gene, the sequence is shown as SEQ ID NO: 1, the circMFN2 is remarkably reduced in a pulmonary arterial hypertension (PH) related sample, IGF2BP3 can be specifically combined, the stabilization effect of IGF2BP3 on PDK4 mRNA is blocked, and the circMFN2 can be used for treating the pulmonary arterial hypertension. Further, mitochondrial energy metabolism is recovered, and abnormal proliferation and migration of pulmonary artery smooth muscle cells are inhibited. The R8 modified circMFN2 liposome preparation disclosed by the invention can play a role in lung tissues after being administered by a nasal cavity, and can be used for remarkably improving indexes such as myelization / middle-layer thickening related to pulmonary arterial smooth muscles.